Altre lingue Corbus Pharmaceuticals Holdings, Inc.

Azioni

CRBP

US21833P3010

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 22/04/2024			Variaz. 5gg	Var. 1 gen.
37,7 ^USD	-3,92%		-11,75%	+524,17%

02/04	Corbus Pharmaceuticals Holdings, Inc. annuncia il dosaggio del primo paziente nello studio clinico di Fase 1 negli Stati Uniti del suo ADC di nuova generazione mirato alla nectina-4	CI
13/03	Corbus Pharmaceuticals deposita una dichiarazione di registrazione mista	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC	02/04
Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC	02/04
Corbus Pharmaceuticals Files Mixed Shelf	13/03
Health Care Climbs on Risk Appetite -- Health Care Roundup	12/03
Corbus Pharmaceuticals: Q4 Earnings Snapshot	12/03
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update	12/03
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12/03
North American Morning Briefing : Inflation Data -2-	12/03
North American Morning Briefing : Powell Still in -2-	07/03
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit	06/03
Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer	29/02
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer	28/02
Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024	06/02
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
Corbus Pharmaceuticals Closes $94.5 Million Public Offering	02/02
Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares	02/02
Corbus Pharmaceuticals Announces Pricing of Public Offering	31/01
Corbus Pharmaceuticals Announces Proposed Public Offering	31/01
Top Premarket Decliners	29/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Corbus Pharmaceuticals Holdings, Inc.

Azioni

CRBP

US21833P3010

Altre lingue

Filtri